[Microstructural retinal changes after pharmacological vitreolysis with ocriplasmin-an SD-OCT supported analysis]

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacological Treatments

Background:

• Ocriplasmin (Jetrea®) is indicated for vitreomacular traction (VMT) with or without small full thickness macular holes (FTMH).
• Previous reports noted retinal alterations following ocriplasmin administration.

Purpose of the Study:

• To evaluate ocriplasmin-associated side effects.
• To assess changes in retinal microstructure after ocriplasmin treatment.

Main Methods:

• Seventy patients receiving ocriplasmin were included.
• Spectral-domain optical coherence tomography (SD-OCT) was used for pre-injection assessment and post-injection evaluation of adverse events.
• Evaluated parameters included macular hole size, macular edema, subretinal fluid, and changes in the ellipsoid zone (EZ) and external limiting membrane (ELM).

Main Results:

• Of 20 patients with FTMH, 8 achieved closure within one week post-injection, and 12 overall closed.
• 51 patients experienced VMT resolution, but 3 developed retinal detachment.
• Retinal microstructure changes (EZ and ELM) were observed in 8 patients.

Conclusions:

• Ocriplasmin is a viable minimally invasive option for VMT and small FTMH.
• Specific, usually transient, side effects are associated with ocriplasmin.
• Severe complications like retinal detachment are rare but possible, necessitating careful patient selection.